
WHAT IS CLAIMED IS:

1. A compound, or a pharmaceutically acceptable salt thereof, wherein the compound is of formula (I):



, wherein

(I)

A is a chelating moiety;


X is selected from the group consisting of $–CH_2C(NH)$-, $–CH_2C(O)$-, $–CH_2C(S)$-, -NHC(NH)-, -NHC(O)-, -NHC(S)-, -OC(NH)-, -OC(O)-, and -OC(S)-, optionally wherein X is $-CH_2C(O)$- or -NHC(S)-;

L is a peptide linker having 1-6 amino acid residues, inclusive;

R^1 is H or C_{1-6} alkyl, optionally wherein R^1 is H or methyl; and

R^2 is C_{1-6} alkyl or C_{3-6} cycloalkyl.

2. The compound, or a pharmaceutically acceptable salt thereof of claim 1, wherein the compound is of formula (Ia):




(Ia).

3. The compound, or a pharmaceutically acceptable salt thereof of claim 1 or claim 2, wherein L has 1-3 amino acid residues, inclusive.

4. The compound, or a pharmaceutically acceptable salt thereof of any one of claim 1-3, wherein L has 3 amino acid residues.


5. The compound, or a pharmaceutically acceptable salt thereof of claim 1, wherein the compound is of formula (Ia-A) or formula (Ia-B):



(Ia-A).

or


~~6. The compound, or a pharmaceutically acceptable salt thereof of claim 1, wherein the compound is of formula (Ia-B):~~




(Ia-B).

6~~7~~. The compound, or a pharmaceutically acceptable salt thereof of any one of claims 1-5~~6~~, wherein the chelating moiety A is 1,4,7-triazacyclononane-N,N′,N′′-triacetic acid (NOTA) or 1,4,7-triazacyclononane-4,7-diyl diacetic acid (NODA).


7~~8~~. The compound, or a pharmaceutically acceptable salt thereof of claim 1, wherein the compound is:




,




,




,




,




,




,




,




,




,




,




,




,



,




,




,


~~or~~




.


~~9. The compound, or a pharmaceutically acceptable salt thereof, of claim 8, wherein the compound is:~~








or



8~~10~~. A compound, or a pharmaceutically acceptable salt thereof, wherein the compound is of formula (II):



, wherein

(II)

M is a metal or a metal linked to a radioisotope;

A is a chelating moiety chelating the metal;


X is selected from the group consisting of –$CH_2C(NH)$-, –$CH_2C(O)$-, –$CH_2C(S)$-, -NHC(NH)-, -NHC(O)-, -NHC(S)-, -OC(NH)-, -OC(O)-, and -OC(S)-, optionally wherein X is -$CH_2C(NH)$- or -NHC(S)-;

L is a peptide linker having 1-6 amino acid residues, inclusive;

R^1 is H or C_{1-6} alkyl, optionally wherein R^1 is H or methyl; and

R^2 is C_{1-6} alkyl or C_{3-6} cycloalkyl.

9~~11~~. The compound, or a pharmaceutically acceptable salt thereof of claim 8~~10~~, wherein the compound is of formula (IIa):




(IIa).

10~~12~~. The compound, or a pharmaceutically acceptable salt thereof of claim 8~~10~~ or claim 9~~11~~, wherein L has 1-3 amino acid residues, inclusive.

11~~13~~. The compound, or a pharmaceutically acceptable salt thereof of any one of claims 8-10~~10-12~~, wherein L has 3 amino acid residues.


12~~14~~. The compound, or a pharmaceutically acceptable salt thereof of claim 8~~10~~, wherein the compound is of formula (IIa-A) or formula (IIa-B):



(IIa-A).

or

~~15. The compound, or a pharmaceutically acceptable salt thereof of claim 10, wherein the compound is of formula (IIa-B):~~



(IIa-B).

13~~16~~. The compound, or a pharmaceutically acceptable salt thereof of any one of claims 8-12~~10-15~~, wherein the chelating moiety A is 1,4,7-triazacyclononane-N,N′,N′′-triacetic acid (NOTA) or 1,4,7-triazacyclononane-4,7-diyl diacetic acid (NODA).


14~~17~~. The compound, or a pharmaceutically acceptable salt thereof of any one of claims 8-13~~10-16~~, wherein the metal is a radioisotope of Gallium (Ga); or wherein the metal is Aluminum (AL), which is linked to the radioisotope.


15~~18~~. The compound, or a pharmaceutically acceptable salt thereof of claim 14~~17~~, wherein the radioisotope of Ga is ^{68}Ga; or wherein the radioisotope linked to Al is ^{18}F.


~~19. The compound, or a pharmaceutically acceptable salt thereof of any one of claims 10-16, wherein the metal is Aluminum (Al), which is linked to the radioisotope.~~


~~20. The compound, or a pharmaceutically acceptable salt thereof of claim 19, wherein the radioisotope is ^{18}F.~~


1621. The compound, or a pharmaceutically acceptable salt thereof of claim 810, wherein the compound is:
































,




,




,




,





, ~~or~~




~~22. The compound, or a pharmaceutically acceptable salt thereof, of claim 21, wherein the compound is:~~









17~~23~~. A pharmaceutical composition comprising a compound of any one of claims 8-16~~10-22~~, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

18.~~24~~ A kit comprising:

(i) a compound, or a pharmaceutically acceptable salt thereof, of any one of claims 8-16~~10-22~~ and

(ii) one or more additional therapeutic agents, wherein the one or more additional therapeutic agents are selected from the group consisting of anti-inflammatory agents, steroids, immunotherapy agents, chemotherapeutic agents, and therapeutic antibodies.

~~25. The kit of claim 24, wherein the one or more additional therapeutic agents are selected from the group consisting of anti-inflammatory agents, steroids, immunotherapy agents, chemotherapeutic agents, and therapeutic antibodies.~~

~~26. A combination therapy comprising a compound of any one of claims 10-22, or a pharmaceutically acceptable salt thereof, as a therapeutic agent and one or more additional therapeutic agents.~~

~~27. The combination therapy of claim 26, wherein the one or more additional therapeutic agents are selected from the group consisting of anti-inflammatory agents, steroids, immunotherapy agents, chemotherapeutic agents, and therapeutic antibodies.~~

19~~28~~. Use of the compound, or a pharmaceutically acceptable salt thereof, of any one of claims 8-16, or the pharmaceutical composition of claim 17, in the manufacture of a medicament for the treatment of ~~A method of treating~~ an immunoregulatory abnormality in a subject in need thereof, ~~the method comprising administering to said subject a combination therapy of claim 26 or claim 27 in an amount effective for treating said immunoregulatory abnormality~~ wherein the immunoregulatory abnormality is selected from the group consisting of an autoimmune disorder, an inflammatory disorder, a skin disorder, cancer, and a cardiovascular disorder.

~~29. The method of claim 28, wherein the immunoregulatory abnormality is selected from the group consisting of an autoimmune disorder, an inflammatory disorder, a skin disorder, cancer, and a cardiovascular disorder.~~

2030. The use~~method~~ of claim 1929, wherein the immunoregulatory abnormality is cancer.

21. The use of claims 19 or 20, wherein one or more additional therapeutic agents is to be further administered to the subject, wherein the one or more additional therapeutic agents is selected from the group consisting of anti-inflammatory agents, steroids, immunotherapy agents, chemotherapeutic agents, and therapeutic antibodies.

22. The use of any one of claims 19-21, wherein the immune response in the treatment of the immunoregulatory abnormality in the subject is monitored by imaging the subject with a suitable imaging technique.

2331. A method of imaging granzyme B in a cell or tissue, a sample, a cell or tissue sample, the method comprising:

contacting the cell or tissue, the sample, the cell or tissue sample with a compound of any one of claims 8-1610~~-22~~, or a pharmaceutically acceptable salt thereof, and

imaging the cell or tissue, the sample, the cell or tissue sample with a suitable imaging technique, thereby imaging granzyme B in the cell or tissue, the sample, the cell or tissue sample;

wherein the compound contains a radioisotope, which optionally is ^{18}F or ^{68}Ga.

~~32. A method of treating an immunoregulatory abnormality in a subject in need thereof, the method comprising administering to said subject a compound of any one of claims 10-22, or a pharmaceutically acceptable salt thereof, in an amount effective for treating said immunoregulatory abnormality.~~

~~33. The method of claim 32, wherein the immunoregulatory abnormality is selected from the group consisting of an autoimmune disorder, an inflammatory disorder, a skin disorder, cancer, and a cardiovascular disorder.~~

~~34. The method of claim 33, wherein the immunoregulatory abnormality is cancer.~~

~~35. The method of any one of claims 32-34, further comprising administering to the subject one or more additional therapeutic agents.~~

~~36. The method of claim 35, wherein the one or more additional therapeutic agents are selected from the group consisting of anti-inflammatory agents, steroids, immunotherapy agents, chemotherapeutic agents, and therapeutic antibodies.~~

~~37. A method of monitoring an immune response in the treatment of a disease in a subject, the method comprising administering to the subject an effective amount of the compound of any one of claims 10-22, or a pharmaceutically acceptable salt thereof, and imaging the subject with a suitable imaging technique.~~

24. The compound, or a pharmaceutically acceptable salt thereof, of any one of claims 8-16, or the pharmaceutical composition of claim 17, for use in therapy.